Literature DB >> 10350016

Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients.

P L Carver1, D Fleisher, S Y Zhou, D Kaul, P Kazanjian, C Li.   

Abstract

PURPOSE: To study the influence of large-volume high-calorie protein, fat, and carbohydrate meals and a non-caloric hydroxypropylmethyl cellulose (HPMC) viscous meal on the oral bioavailability of indinavir in HIV-infected subjects.
METHODS: Seven male HIV-infected subjects received caloric meal treatments and control meals in a randomized crossover fashion and the viscosity meal as a final treatment. The total volume of each meal treatment was 500 mL and the caloric meals each contained 680 kcal. Gastric pH was also monitored by radiotelemetry from one hour before to four hours after drug and caloric meal administration. A single Crixivan (indinavir sulfate) dose equivalent to 600 mg indinavir was administrated orally with 100 mL of water immediately following meal administration. Indinavir plasma concentrations were obtained using reverse-phase HPLC.
RESULTS: All meal treatments significantly decreased the extent of indinavir absorption as compared to fasted control. AUC0-infinity decreased by 68%, 45%, 34%, and 30% for protein, carbohydrate, fat, and viscosity meal treatments versus fasted control, respectively (p < 0.05). The mean Cmax was significantly decreased 74%, 59%, 46% and 36% (p < 0.05) and the mean tmax was significantly delayed from I hr in fasted controls to 3.8, 3.6, 2.1 and 2.0 hrs (p < 0.05) for protein, carbohydrate, fat, and viscosity meal treatments, respectively. The elimination half-life of indinavir determined in the fasted state was decreased in HIV-infected subjects as compared to the reported half-life in normal healthy subjects.
CONCLUSIONS: Reductions in indinavir plasma concentrations compared to drug administration in the fasted state are most severe with the high-calorie protein meal. This is consistent with an influence of elevated gastric pH on drug precipitation. Significant drug plasma concentration reductions observed with administration of the other meals in the absence of appreciably elevated gastric pH profile indicate that other factors are playing a role in the meal effects. The similarity in indinavir plasma profiles with protein and carbohydrate versus fat and viscosity suggests that the latter meals may reduce the impact of drug precipitation compared to the former meals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350016     DOI: 10.1023/a:1018880726035

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Nelfinavir.

Authors:  C M Perry; P Benfield
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs.

Authors:  C Reppas; J H Meyer; P J Sirois; J B Dressman
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

3.  CCK antagonist pre-treatment inhibits meal-enhanced drug absorption in dogs.

Authors:  C Miles; P Dickson; K Rana; C Lippert; D Fleisher
Journal:  Regul Pept       Date:  1997-01-15

4.  Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.

Authors:  D M Burger; M de Graaff; E W Wuis; P P Koopmans; Y A Hekster
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-12-05

5.  Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.

Authors:  S K Balani; E J Woolf; V L Hoagland; M G Sturgill; P J Deutsch; K C Yeh; J H Lin
Journal:  Drug Metab Dispos       Date:  1996-12       Impact factor: 3.922

Review 6.  Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

7.  Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption.

Authors:  L H Pao; S Y Zhou; C Cook; T Kararli; C Kirchhoff; J Truelove; A Karim; D Fleisher
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

8.  Interaction between bile salts and beta-adrenoceptor antagonists.

Authors:  M P Grosvenor; J E Löfroth
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

9.  L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

Authors:  B D Dorsey; R B Levin; S L McDaniel; J P Vacca; J P Guare; P L Darke; J A Zugay; E A Emini; W A Schleif; J C Quintero
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

10.  pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.

Authors:  J H Lin; I W Chen; K J Vastag; D Ostovic
Journal:  Drug Metab Dispos       Date:  1995-07       Impact factor: 3.922

View more
  17 in total

1.  Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

Authors:  T N Kakuda; L M Page; P L Anderson; K Henry; T W Schacker; F S Rhame; E P Acosta; R C Brundage; C V Fletcher
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

4.  Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.

Authors:  Bregt S Kappelhoff; Alwin D R Huitema; Sanjay U C Sankatsing; Pieter L Meenhorst; Eric C M Van Gorp; Jan W Mulder; Jan M Prins; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

5.  Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Authors:  Hannah M Jones; Neil Parrott; Gerd Ohlenbusch; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

Authors:  Joseph M Custodio; Chi-Yuan Wu; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2007-11-28       Impact factor: 15.470

Review 7.  A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Richard N Upton
Journal:  AAPS J       Date:  2016-07-20       Impact factor: 4.009

Review 8.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

9.  Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

Authors:  Reza Khosravan; Brian Grabowski; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.